№ files_lp_4_process_3_103173
File format: docx
Character count: 30857
File size: 42 KB
Transcript of a health podcast discussing the role of essential fatty acids in human biology, sources of omega-3 and omega-6, and their influence on inflammation and microbiome health.
Year:
2026
Region / City:
Berkshires, New York City
Topic:
Nutrition, Essential Fatty Acids, Microbiome
Document Type:
Podcast Transcript
Organization / Institution:
The Health Edge
Speakers:
Mark [host], Dr. John Bagnulo
Audience:
General public interested in health and nutrition
Event:
Integrative Health Symposium
Date of Recording:
March 2026
Key Subjects:
Omega-3, Omega-6, Glyphosates, Inflammation, Microbiome
Scientific Focus:
Dietary fats, hormone production, eicosanoids
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Organization:
National Institute for Health and Care Excellence
Centre:
Centre for Health Technology Evaluation
Committee:
Diagnostics Advisory Committee
Document type:
Meeting minutes
Meeting date:
28 September 2022
Location:
Via Zoom
Session type:
Open session
Chair:
Brian Shine
Topic:
Evaluation of MRI-based technologies for assessing non-alcoholic fatty liver disease
Participants:
Committee members, NICE staff, external assessment groups, external assessment centres, specialist committee members, experts, observers
Conflicts of interest:
Declarations recorded
Approval status:
Minutes confirmed
Year:
2021
Region / City:
Australia / New Zealand
Subject:
Food Additives
Document Type:
Risk Assessment
Organization / Institution:
FSANZ
Author:
FSANZ
Target Audience:
Food Safety Authorities, Researchers, Food Industry
Period of Validity:
Not specified
Approval Date:
9 February 2021
Amendment Date:
Not specified
Year:
2022
Region / city:
Nanjing
Topic:
Hepatocellular Carcinoma, Gut Microbiota, Immunology
Document type:
Supplementary Materials
Organization / institution:
Nanjing Medical University
Author:
Chupeng Hu, Bingqing Xu, Yun Chen
Target audience:
Researchers, scientists, medical professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Name:
Mr Wong
Age:
45
Gender:
Male
Diagnosis:
Non-Alcoholic Fatty Liver Disease (NAFLD)
Occupation:
Software Developer
Document Type:
Clinical interview and dietary assessment report
Medical Condition:
Non-Alcoholic Fatty Liver Disease
Assessment Focus:
Dietary habits and lifestyle changes
Pre-Diagnosis Diet Characteristics:
High intake of refined carbohydrates, sugars, saturated and trans fats; frequent sugary drinks and alcohol consumption
Post-Diagnosis Diet Characteristics:
Increased intake of whole grains, lean proteins, healthy fats, and fibre; reduced refined sugars, saturated fats, sugary drinks, and alcohol
Lifestyle Factors:
Physical activity and weight management
Recommendations:
Dietary modification, increased omega-3 intake, portion control, increased physical activity
Plan:
Follow-up appointments, dietitian referral, educational materials, personalized exercise plan
Includes:
Patient reflection statement
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Organisations:
European Society for Paediatric Gastroenterology Hepatology and Nutrition; European Association for the Study of the Liver
Type of document:
Joint statement
Thematic area:
Paediatric hepatology; fatty liver disease; NAFLD; MAFLD
Subject:
Diagnostic approach to hepatic steatosis in children and adolescents
Target audience:
Paediatricians; hepatologists; clinicians
Geographical scope:
Europe
Key terms:
Non-alcoholic fatty liver disease (NAFLD); metabolic dysfunction-associated fatty liver disease (MAFLD); insulin resistance; metabolic syndrome; Wilson’s disease; autoimmune hepatitis
Referenced process:
Global multi-stakeholder Delphi consensus on nomenclature and definition of fatty liver disease
Correspondence:
[email protected]
Year:
NA
Region / City:
Mumbai
Topic:
Safety Data Sheet
Document Type:
Material Safety Data Sheet
Organization:
Pranav Agro
Author:
NA
Target Audience:
NA
Effective Period:
NA
Approval Date:
NA
Date of Changes:
NA
Year:
2021
Region / City:
Americas, Europe
Subject:
Oleochemical Industry, Catalysts
Document Type:
Technical Paper
Organization / Institution:
Evonik Industries
Author:
Evonik Catalysts Team
Target Audience:
Professionals in oleochemical manufacturing, researchers in catalysis
Period of Effect:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Organization:
International Society for the Study of Fatty Acids and Lipids (ISSFAL)
Document type:
Official statement
Statement number:
5
Topic:
Alpha-linolenic acid supplementation and conversion to n-3 long chain polyunsaturated fatty acids
Subject area:
PUFA nutrition
Authors:
J. Thomas Brenna; Norman Salem, Jr.; Andrew J. Sinclair; Stephen C. Cunnane
Affiliations:
Division of Nutritional Sciences, Cornell University; Martek Biosciences, Inc.; Deakin University, School of Exercise & Nutrition Sciences; Research Center on Aging, Université de Sherbrooke
Approval body:
ISSFAL Board of Directors
Geographical scope:
International
Population focus:
Humans and mammals, including infants and adults
Key substances:
Alpha-linolenic acid (ALA); Eicosapentaenoic acid (EPA); Docosapentaenoic acid (DPA); Docosahexaenoic acid (DHA); Linoleic acid (LA)
Type of evidence:
In vivo metabolic studies; tracer studies with stable isotopes; animal tissue compositional studies; human blood and breast milk analyses
Dietary context:
Western diets rich in linoleic acid
Document type:
Supplementary tables to a scientific research article
Subject:
Nutritional composition and physiological effects of nano-selenium in on-growing grass carp
Study organism:
On-growing grass carp
Experimental groups:
RD; HFD; HSe0.3; HSe0.6
Dietary treatments:
Regular diet; high-fat diet; high-fat diet supplemented with 0.3 mg/kg nano-Se; high-fat diet supplemented with 0.6 mg/kg nano-Se
Measured parameters:
Growth performance; gene expression primers; fatty acid composition of muscle
Nutrients analyzed:
Crude protein; crude lipid; selenium levels; fatty acids (SFA, MUFA, PUFA, n-3 PUFA, n-6 PUFA)
Genes analyzed:
β-actin; MyoD; MyoG; PPARα; ATGL; LPL; HSL; PI3K; AKT; TOR; S6K1; 4E-BP1; GLDH
Data presentation:
Mean ± SD (n = 3); statistical significance at P < 0.05
Language:
English
Authors:
Petar Avramovski; Julijana Petrovska; Maja Avramovska
Affiliations:
St. Clement of Ohrid University – Bitola; Clinical Hospital – Bitola
Country:
North Macedonia
City:
Bitola
Medical Field:
Gastroenterology; Hepatology; Diagnostic Ultrasound
Type of Document:
Scientific research abstract
Study Design:
Observational clinical study
Study Population:
325 patients with non-alcoholic fatty liver disease (NAFLD)
Average Age of Participants:
54.2±8.5 years
Institutions Involved:
Department of Ultrasonography; Department of Gastroenterohepatology; Department of Gynecology and Obstetrics, Clinical Hospital – Bitola
Methods:
B-mode ultrasound imaging, echogenicity analysis software, laboratory tests for platelets, ALT and AST, calculation of FIB-4 score
Diagnostic Indicators Studied:
Hepatorenal Index (HRI); Fibrosis-4 (FIB-4) score
Conditions Examined:
Non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; liver fibrosis; cirrhosis
Patient Group Classification:
Mild NAFLD; moderate NAFLD; severe NAFLD; significant fibrosis (≥F2); advanced fibrosis (≥F3); cirrhosis (F4)
Keywords:
hepatorenal index; FIB-4 score; NAFLD; liver fibrosis; cirrhosis; ultrasound diagnostics
Year:
1930s
Region / City:
Northern Canada
Subject:
Indigenous Residential School Experiences
Document Type:
Book Excerpt
Author:
Christy Jordan-Fenton and Margaret Pokiak-Fenton
Target Audience:
Young adults
Main Character:
Olemaun
Setting:
Home community and residential school
Themes:
Cultural clash, family decisions, childhood curiosity, adaptation to school rules
Historical Context:
Residential schools in Canada
Year:
2023
Region / City:
United States
Topic:
Non-alcoholic fatty liver disease, Ethylene oxide exposure
Document Type:
Research Supplement
Author:
Shiwei Yan, Haolong Pei, Qian Li, Wenzhe Cao, Yan Dou, Shihan Zhen, Qingyao Wu, Fengchao Liang
Target Audience:
Researchers, Public Health Professionals
Period of Validity:
2013-2018
Approval Date:
Not specified
Date of Changes:
Not specified
Name of medicinal product:
FORTALINE® PLUS Omega 3 fatty acids – vitamin E
Strength:
500 mg marine lipid concentrate (18% EPA, 12% DHA) – 10 mg vitamin E
Pharmaceutical form:
Soft capsule
Composition:
Marine lipid concentrate (fish oil) and α-tocopheryl acetate (vitamin E)
Active substances:
Omega-3 fatty acids (EPA, DHA), Vitamin E
Technology:
EnteriCare™ Anti-Reflux Technology
ATC code:
C10AX06; A11HA03
Pharmacotherapeutic group:
Other lipid modifying agents; Other plain vitamins
Route of administration:
Oral use
Recommended dosage (adults):
One to two capsules per day
Recommended dosage (pregnant and lactating women):
Two to three capsules per day
Recommended dosage (children able to swallow capsules):
One capsule per day
Therapeutic indications:
Dietary supplementation with omega-3 fatty acids for nutritional balance and physiological support
Contraindications:
Hypersensitivity to ingredients; concomitant use with aspirin or anticoagulants such as warfarin; patients at high risk of bleeding
Adverse reactions:
Gastrointestinal disorders, nausea, dyspepsia, rash, bruising, belching, diarrhoea, heartburn, bad breath
Pharmacological components:
Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), Vitamin E
Target populations:
Adults, pregnant and lactating women, children able to swallow capsules
Document type:
Medicinal product summary of characteristics
Field:
Pharmacology / dietary supplementation
Note:
Year
Theme:
Biochemistry
Document type:
Lecture notes
Target audience:
Students of biochemistry
Year:
2024
Region / city:
Australia
Topic:
Dietary management of Phenylketonuria (PKU)
Document type:
Submission
Organization:
PBAC
Author:
Committee Secretariat
Target audience:
Medical practitioners, nurse practitioners
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / City:
California
Subject:
Environmental Monitoring, Chemical Analysis
Document Type:
Technical Report
Organization / Institution:
California Water Board
Author:
Department of Defense
Target Audience:
Laboratories, Environmental Agencies
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
Australia / New Zealand
Subject:
Food Additives
Document Type:
Risk Assessment
Organization / Institution:
FSANZ
Author:
FSANZ
Target Audience:
Food Safety Authorities, Researchers, Food Industry
Period of Validity:
Not specified
Approval Date:
9 February 2021
Amendment Date:
Not specified
Year:
2023
Region / City:
Australia
Topic:
Food for medical purposes, dietary supplements
Document Type:
Submission
Agency / Institution:
Vitaflo Australia Pty Limited
Author:
Not specified
Target Audience:
Healthcare professionals, pharmaceutical regulators
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2026
Region / City:
Australia
Topic:
Nutritional Formulation, Food for Special Medical Purposes
Document Type:
Submission to PBAC
Organization / Institution:
PBAC, Nutricia Australia Pty Ltd
Author:
Nutricia Australia Pty Ltd
Target Audience:
Healthcare professionals, regulatory bodies, pediatricians
Validity Period:
Ongoing
Approval Date:
1 August 2002
Date of Change:
2011, 2026
Requested Change:
Formulation modification to comply with EU regulations
Status:
Approved for continued listing